Editas Medicine, Inc.

Direct answer

Editas Medicine, Inc. is publicly traded on NASDAQ under the ticker EDIT.

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also...

Can you invest in Editas Medicine, Inc.?

Yes. Editas Medicine, Inc. is publicly traded on NASDAQ under the ticker EDIT.

View deeper analysis

View detailed research on MarketSnap, including financials, valuation tools, and analyst context.

Open research for Editas Medicine, Inc.

Detailed equity research is provided by MarketSnap.